#1SUVEN PHARMA SUVEN PHARMA Earnings Presentation Q1 FY24#2Risk Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven Pharma attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharma may not undertake to update any forward-looking statements that may be made from time to time. SUVE 2 PHARMA#34 14 Table of Contents Operation & Financial Performance Q1 FY24 Company Background SUVEN PHARMA 3#4Operation & Financial Performance Q1 FY24 SUVEN PHARMA 4#5Businesswise data 210.23 CDMO Pharma CDMO Spec Chem Formulations & Other 256.45 117.35 245.97 72.74 75.35 11.22 Services 35.2 22.7 Q1 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q4 FY23 Q1 FY24 Note: Figures in Rs. Crore SUVEN 5 PHARMA#6Financial Snapshot Growth in Revenue Growth in EBITDA Q1FY24 Q1FY23 Growth in PAT -5.61% -2.94% -4.51% 1.25% 8.64% 8.98% Comparison with immediate previous quarter and same quarter of previous year SUVEN 6 PHARMA#7Key Ratios EBIT to Income EBITDA to Income Q1FY24 Q1FY23 PAT to Income 50.82% 35.10% 47.67% 44.35% 47.37% 32.61% SUVEN PHARMA#8RUPEES MN - Financials Comparison Q1FY24 to earlier periods Revenue EBIDTA PAT 3,751 1,854 1,302 3,497 3,541 1,799 1,243 1,656 1,141 RUPEES MN RUPEES MN RUPEES Q1 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q4 FY23 Q1 FY24 4.5 SUVEN ☐ 8 PHARMA EPS 5.1 4.9#9Financials Comparison - Q1FY24 to earlier periods 47% EBITDA Margin (%) 49% 51% PAT Margin (%) 33% 35% 35% Q1 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q4 FY23 Q1 FY24 SUVEN 9 PHARMA#10Financial Snapshot Quarter ended 30-Jun-23 31-Mar-23 30-Jun-22 Revenue from operations Other Income 3,440.26 3,643.90 3,387.99 Year ended 31-Mar-23 13,300.80 100.59 107.55 108.98 445.52 Total Income 3,540.85 3,751.45 3,496.97 13,746.32 EBITDA 1,799.41 1,853.83 1,656.37 6,276.30 EBITDA Margin 50.82% 49.42% 47.37% 45.66% EBIT 1,687.93 1,747.55 1,550.89 5,847.85 EBIT Margin 47.67% 46.58% 44.35% 42.54% Finance costs 11.47 22.90 14.33 Depreciation 111.48 106.27 105.48 53.92 428.45 Taxes 433.53 423.04 396.05 1,467.91 Taxes to PBT 25.86% 24.53% 25.78% 25.34% PAT (Standalone) 1,242.94 1,301.62 1,140.52 4,326.03 PAT Margin (Standalone) 35.10% 34.70% 32.61% 31.47% Associate Company PAT (Consolidated) 1,205.90 1,239.71 1,075.42 4,112.90 PAT Margin (Consolidated) 34.06% 33.05% 30.75% 29.92% EPS (Standalore) 4.88 5.11 4.48 16.99 EPS (Consolidated) 4.74 4.87 4.22 16.16 Paid up share capital (Re.1/sh) 254.56 254.56 254.56 254.56 All figures are in INR Million, other than ratios and EPS SUVEN 10 PHARMA#11Notes and updates A The Promoter Group, Jasti Property and Equity Holdings Private Limited (in their capacity as sole trustee of Jasti Family Trust), informed the Company that they executed a Share Purchase Agreement to sell 12,75,37,043 Equity shares representing 50.10% of the Voting share capital to Berhyanda Limited on 26th December 2022. The transaction is not yet closed, waiting for necessary approvals from Government of India. SUVEN PHARMA 11#12Company Background SUVEN PHARMA 12#13Business Model DO HO Process Research Contract Development And Manufacturing Operations (CDMO) Custom Synthesis Formulation Development Analytical & Services Clinical Supplies Mfg & Packaging DDI உ SUVEN 13 PHARMA#14Brief Profile BUSINESS OVERVIEW o Integrated CDMO company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing. KEY STRENGTHS 。 Preferred global outsourcing partner with capabilities across the entire CDMO value chain. • Strong chemistry skills. FINANCIAL OVERVIEW 。 Standalone Revenues, EBITDA and Adj. PAT of Rs 3541 Mn, Rs 1799 Mn and Rs 1243 Mn in Q1-FY24. o Strong balance sheet with D:E ratio of less than 0.02 as on Jun-23. SUVEN 14 PHARMA#15Brief Overview Suven is an integrated Contract Development and Manufacturing Operations company Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Since our founding in 1989 (pre-demerger), Suven has established its core competency in cyanation and heterocyclic chemistry, including pyrimidines, quinolones, thiazoles, and imidazoles, in addition to demonstrating our proficiency in Carbohydrate and Chiral chemistry including tetrahydrofurans, amino acids and sulfoxides from gram to multi-ton scale. Suven effectively uses its expanding infrastructure and ability to collaborate, from route scouting and development through commercial manufacture, to provide a consistent and reliable partner throughout a product's life cycle. Suven is dedicated to going beyond commitment and delivering R&D and Manufacturing solutions, with flexibility, quality, speed, and cost effectiveness. SUVEN 15 PHARMA#16Our Focus A full-fledged bio- pharmaceutical solutions provider for global pharmaceutical companies NCE based CDMO SUVEN 116 PHARMA#17Financial Approach Low debt FA Shareholder value creation focus Consistently dividend paying E Prudent utilisation of cash flows SUVEN 17 PHARMA#18Business Drivers Industry Relationship State of the art facilities located across India and US Present across the entire CDMO value chain - intermediates & APIs Leveraging on research capabilities to delivering NCE research TUJU An integrated research service provider with unmatched capabilities 00 SUVEN PHARMA 18#19Business Drivers Repeat business owing to long standing relationships with MNC companies Execution Capabilities Long term commercial supply with the launch of product by global sponsors Working with innovator companies in developed markets having stringent regulations - reflection of our research skills Over 90% of revenues from regulated markets ՄՌ m SUVEN 19 PHARMA#20Multi Location Facilities Vizag, Andhra Pradesh, India 。 307 KL reactor volume o 3KL to 12KL Reactors 。 GL/SS (45No's) o API's/Advanced Intermediate's/CMO Pashamylaram, Telangana, India API & Formulation Facility o 120 KL reaction volume 。 50L-6000 L GL/SS (45) 。 API Manufacturing o Formulation R&D о 300 CM reactors (93) о 500L to 10 KL GL/SS Banjara Hills, Hyderabad, India Corporate Office о GMP Intermediates Suryapet, Telangana, India Intermediate Mfg. Facility o Process Research 。 Analytical R&D o Killo lab, 30L CM Reactors (32) o 50L 4000 L GL/SS Jeedimetla, Telangana, India R&D-Pilot Plant o Business Development o Project Management USA, New Jersey Business Office SUVEN 20 PHARMA#21Contact Suven Pharmaceuticals Ltd # 8-2-334, SDE Serene Chambers, 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-500 034, Telangana, INDIA. +91-40-2354-9414/1142/3311 For queries and requests, please contact: Sunder Venkatraman Suven Pharmaceuticals Ltd Tel: +91 939 248 3011 Email: [email protected] For more info: www.suvenpharm.com Gavin Desa Rishab Barar CDR - India Tel: +91 22 6645 1237 / 1235 Email: [email protected] [email protected] SUVEN 21 PHARMA#22Thank You SUVEN PHARMA